3D BioLabs
Develops 3D printed implantable hydrogel devices with intrinsic vascular channels for liver tissue engineering, aiming to address organ transplant shortages through regenerative medicine.
- CEO / Founder
- Joseph P. Vacanti
- Team Size
- 11-50
- Stage
- Active
- Total Funding
- $1.2M
- Latest Round
- Seed
- Key Investors
- Gardner Lewis Ventures, LLC
Technology & Products
Key Products
3D printed liver implant device with portal-venous and hepatobiliary channels
Technological Advantage
Scientific Founder Joseph P. Vacanti's decades of groundbreaking research in tissue engineering; platform combines 3D printing with cell biology to mimic native organ structure and function.
Differentiation
Value Proposition
Provides a platform technology to create living tissue human organs, potentially eliminating donor shortages and reducing transplant wait times (currently 100,000+ patients on US waiting lists).
How They Differentiate
Focuses specifically on implantable organs (liver) with intrinsic vascularization vs. competitors' broader focus on bioprinters, bioinks, or tissue models for drug testing.
Market & Competition
Target Customers
Hospitals, transplant centers, and patients suffering from organ failure (liver, other organs) and complex tissue loss (e.g., military blast injuries).
Industry Verticals
Medical; Biotechnology; Regenerative Medicine
Competitors
Organovo (VivoSim Labs); BICO (CELLINK); 3D Systems (Desktop Health)
Growth & Milestones
Growth Metrics
Achieved a pivotal milestone with a PNAS study published December 5, 2024, demonstrating blood flow and cell viability in a 3D printed liver device model, supported by pig implants up to one week.
Major Milestones
Published landmark study in Proceedings of the National Academy of Sciences demonstrating new approach for producing large organs (2020); Achieved pivotal milestone in development of 3D printed liver implant (2024)